FibroBiologics (FBLG) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
FibroBiologics is the larger company by market cap ($8.0 million vs $134,320), about 59.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBLG | MDCX |
|---|---|---|
| Share price | $1.15 | $0.0896 |
| Market cap | $7.99M | $134.32K |
| 1-day change | +3.45% | -12.07% |
| YTD return | — | -93.34% |
| 1-year return | — | -95.86% |
| EPS (TTM) | $-5.01 | $-119.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.98 | $139.00 |
| 52-week low | $0.62 | $0.084 |
| Distance from 52-week high | -88.49% | -99.94% |
| Analyst consensus | none | none |
| Avg. price target upside | +988.57% | +4922.32% |
| Average volume | 204.44K | 92.96K |
| Shares outstanding | 6.96M | 1.50M |
| Employees | 15 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FibroBiologics is about 59.5 times larger than Medicus Pharma by market value ($7.99M vs $134.32K).
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
FBLG vs MDCX FAQ
Which is bigger, FibroBiologics or Medicus Pharma?
FibroBiologics (FBLG) is larger, with a market capitalization of $7.99M compared with $134.32K for Medicus Pharma (MDCX).
Are FibroBiologics and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.